Improving health-related quality of life in non-small-cell lung cancer with current treatment options

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations

Abstract

Non-small-cell lung cancer (NSCLC) accounts for > 80% of all lung carcinomas, with the majority of patients presenting with late-stage disease. Selection of an appropriate therapy depends on the stage of disease, with treatment of patients with advanced NSCLC often aimed at palliation of symptoms and improving the well-being of patients. Health-related quality of life (QOL) has been largely ignored as an endpoint in clinical trials for NSCLC, but there is increasing acceptance by clinicians and regulatory authorities that alleviation of symptoms and improved health-related QOL should be carefully considered. This article discusses current approaches to measuring health-related QOL. This discussion is followed by a brief review of some of the current treatment options for patients with NSCLC and their effect on health-related QOL.

Original languageEnglish (US)
Pages (from-to)206-212
Number of pages7
JournalClinical Lung Cancer
Volume9
Issue number4
DOIs
StatePublished - Jul 2008

Keywords

  • Docetaxel
  • Erlotinib
  • Gefitinib
  • Pemetrexed
  • Second-line therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Improving health-related quality of life in non-small-cell lung cancer with current treatment options'. Together they form a unique fingerprint.

Cite this